This Penny Stock Is Betting Big on Meme Crypto BONK. Should You Buy SHOT Shares Here?

Safety Shot (SHOT) has made a bold move into cryptocurrency by allocating $25 million to BONK (BONK), the fifth-largest memecoin with a market cap of over $2 billion. Last week, the Nasdaq-listed company the creation of a corporate BONK treasury, receiving $25 million in tokens through a strategic alliance with BONK founding contributors, while issuing $35 million in convertible preferred shares as consideration.

This positions Safety Shot among an increasing number of companies adopting altcoin treasury strategies beyond Bitcoin (BTCUSD). Recent corporate moves include Bit Origin (BTOG) arranging $500 million for Dogecoin (DOGEUSD) accumulation and SharpLink Gaming (SBET) disclosing nearly 600,000 in Ethereum (ETHUSD) holdings. Safety Shot CEO Jarrett Boon called it “the first stage of a much broader corporate evolution for our company” and a bold step into digital assets.

Safety Shot chose BONK for its Solana (SOLUSD) blockchain foundation, citing high-speed, low-cost transaction capabilities that provide advantages over Ethereum-based competitors like Shiba Inu (SHIBUSD) and Pepe (PEPE), which wrestle with network congestion and elevated fees.

Notably, Safety Shot’s core business focuses on beverages designed to reduce blood alcohol content, generating revenue through direct-to-consumer sales and retail partnerships. While the company has over $15 million in cash reserves, this crypto pivot represents a dramatic shift from its healthcare-focused mission. Though corporate crypto adoption is accelerating, investors should carefully consider whether this speculative bet aligns with their risk tolerance before purchasing SHOT shares.

Safety Shot presents substantial risks for potential investors, even as recent clinical trials showed significant blood alcohol content (BAC) reduction. As of June 2025, Safety Shot held just $466,791 in cash with negative working capital of $3.0 million, raising substantial doubt about its ability to continue as a going concern. This financial distress follows years of mounting research and development expenses, including $1.6 million in 2023 alone, while generating minimal revenue since launching its Sure Shot supplement in December 2023.